Published in Therap Adv Gastroenterol on July 01, 2009
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol (2014) 0.86
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging (2015) 0.85
Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int (2013) 0.82
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol (2015) 0.79
Biomarkers in Search of Precision Medicine in IBD. Am J Gastroenterol (2016) 0.79
Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol (2014) 0.77
Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. Sci Rep (2015) 0.77
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol (2016) 0.76
Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther (2016) 0.76
Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol (2014) 0.75
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol (2016) 0.75
Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. Prz Gastroenterol (2015) 0.75
Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140. Sci Immunol (2017) 0.75
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. World J Gastroenterol (2017) 0.75
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology (2002) 1.80
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis (2005) 1.61
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis (2007) 1.33
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol (2002) 1.32
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther (2003) 1.22
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 1.20
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology (2001) 1.18
Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther (2004) 1.13
Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J (2002) 1.05
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther (2005) 1.05
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol (2002) 1.03
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics (2002) 0.98
Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther (2003) 0.96
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis (2007) 0.95
High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol (2002) 0.95
IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J Gastroenterol (2005) 0.90
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis (2004) 0.85
Prediction of response to infliximab in Crohn's disease. Dig Liver Dis (2005) 0.79
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum (2009) 1.53
Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis (2012) 1.42
A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. Ann Surg (2014) 1.41
Significant variation in recommendation of care for women of reproductive age with ulcerative colitis postileal pouch-anal anastomosis. Dig Dis Sci (2014) 1.40
Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis (2010) 1.25
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol (2008) 1.08
Acute Pancreatitis-Progress and Challenges: A Report on an International Symposium. Pancreas (2015) 1.01
Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98
Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine (2011) 0.96
GERD symptoms in the general population: prevalence and severity versus care-seeking patients. Dig Dis Sci (2014) 0.96
Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.94
Improving quality of care in IBD: a STEEEP challenge. Inflamm Bowel Dis (2010) 0.90
Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2013) 0.89
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis (2014) 0.89
Variants in ZNF365 isoform D are associated with Crohn's disease. Gut (2011) 0.87
Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study. J Cutan Med Surg (2014) 0.87
Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature. J Clin Rheumatol (2004) 0.86
New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci (2009) 0.85
Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis (2013) 0.85
Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers. Inflamm Bowel Dis (2016) 0.84
Video capsule endoscopy impacts decision making in pediatric IBD: a single tertiary care center experience. Inflamm Bowel Dis (2013) 0.83
Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. Arthritis Care Res (Hoboken) (2014) 0.83
Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis (2016) 0.83
Immunizations and IBD: whose responsibility is it? If I'm the prescribing doctor, shouldn't it be mine? Inflamm Bowel Dis (2011) 0.82
Implementing quality measures for inflammatory bowel disease. Curr Gastroenterol Rep (2015) 0.82
Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. Qual Life Res (2014) 0.81
A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. Dis Colon Rectum (2010) 0.79
Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease? Dis Colon Rectum (2012) 0.79
Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. Gastroenterol Hepatol (N Y) (2012) 0.79
Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci (2012) 0.79
Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci (2015) 0.78
Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. Inflamm Bowel Dis (2017) 0.76
Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med (2014) 0.76
Proximal small intestinal CD detected by CE. Gastrointest Endosc (2008) 0.75
High-dose perioperative corticosteroids in steroid-treated patients undergoing major colorectal surgery: necessary or overkill? Am J Surg (2012) 0.75
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75
Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.75
The impact of medical therapy for inflammatory bowel disease on pregnancy outcome. Am J Gastroenterol (2008) 0.75
Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol (2012) 0.75
Corrigendum: ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol (2017) 0.75
Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis (2016) 0.75
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2017) 0.75
Facial ulceration in a patient with Crohn's disease. Gastroenterology (2012) 0.75
Clinical Factors Associated with the Development of Crohn's Disease in Inflammatory Bowel Disease-unclassified Patients Undergoing Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis (2016) 0.75
Patient-Reported Outcomes of Quality of Life, Functioning, and GI/Psychiatric Symptom Severity in Patients with Inflammatory Bowel Disease (IBD). Inflamm Bowel Dis (2017) 0.75
Comparison of adenoma detection rates between gastroenterologists and colorectal surgeons. Am Surg (2012) 0.75
Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 0.75
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis (2016) 0.75
Corrigendum: development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol (2015) 0.75